|Day Low/High||2.20 / 2.24|
|52 Wk Low/High||1.50 / 3.15|
Results expected in second half of 2020
Clinical-stage programs on track with results expected from three trials in 2020 Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.
Webcast and Conference Call to be Held at 4:30 p.m. EDT on August 1, 2019
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Webcast and Conference Call to be Held at 4:30 p.m. EST on March 8, 2018
Data Support Potential of OTO-413 as a Treatment for Synaptopathy-Related Hearing Loss
Investors in Otonomy Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OTIC options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.
Conference call and webcast today at 4:30 p.m. EST
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 8, 2017
Investors in Otonomy Inc saw new options begin trading this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.
Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Otonomy, Inc.
Levi & Korsinsky announces it has commenced an investigation of Otonomy, Inc.
The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.